Released on: April 27, 2008, 11:37 pm

Press Release Author: Energy Business Reports

Industry: Biotech

Press Release Summary: The research report "Biotechnology in the European Union;
Trends, Investing & Country Profiles"
(http://www.bharatbook.com/detail.asp?id=73233) provides the detailed information
about the upcoming opportunities in european biotechnology.

Press Release Body:
Biotechnology is often considered to be one of the key technologies that will help
enable the long-term sustainable development of the European Union (EU),
particularly in terms of economic growth, environmental protection and public
health. At its March 2000 Lisbon summit the European Council endorsed the objective
of making the EU "the most competitive and dynamic knowledge-based economy in the
world, capable of sustainable economic growth with more and better jobs and greater
social cohesion". In 2005 the
Lisbon Strategy was refocused on economic growth and more and better jobs.

The biotechnology products and processes are an integral part of the EU economy,
particularly in manufacturing, including pharmaceuticals, agro-food and health care.
While some products are invisible to the general public - like use of genetic
markers in livestock breeding, etc - others are used on a daily basis - detergents
with enzymes and recombinant insulin - or have become a topic of public discussion
e.g. genetically modified crops.

The predominance of the health sector in European biotechnology is visible from the
distribution of dedicated biotechnology firms by sector. According to Critical I
report, 37% of biotechnology companies in 18 European countries (including Norway
and Switzerland) were active in the human health care sector while another 18% were
classified as active in biodiagnostics, which also includes health care diagnostics.
Companies active in agricultural and environmental biotechnology make up 11% of all
the biotech companies and 34% of the biotechnology companies provide services such
as bioprocessing and screening.

The competitiveness of the EU in developing biotechnology applications depends on
the EU's capacity for conducting research, generating new knowledge and converting
it into new products and processes. Stimulating research, but also promoting take-up
of innovations and encouraging entrepreneurship in biotechnology to reap the
economic returns that can be generated from the research results, have been
identified as challenges for the EU.

The European biotech industry is investing strongly in the future and is funding
large increases in research and development (R&D). R&D expenses have increased by
22% for publicly traded companies and by 15% for the industry as a whole. The
industry's longterm growth can only be secured through strong R&D activities. On
average, publicly traded European biotech companies are reinvesting about a third of
their total revenues in R&D, a strong proof of their dedication to long-term growth.
Compared to the beginning of century, many European companies are now better placed
to tap into the biotech industry\'s momentum in the region. Throughout Europe, local
governments are striving towards new levels of excellence and the industry overall,
is benefiting from focused efforts.

For more reports on biotechnology visit us at:
http://www.bharatbook.com/category.asp?catid=40

Web Site: http://www.bharatbook.com/detail.asp?id=73233

Contact Details: Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com